Fertility Preservation: Nonsurgical and Surgical Options

ABSTRACT

Improved surveillance and treatment regimens have resulted in decreased mortality rates among cancer patients, allowing these women to focus on survival and quality of life, including the ability to preserve their fertility. The treatments that have improved survival among both adults and children diagnosed with cancer are often gonadotoxic, especially those that employ high doses of alkylating agents and radiation therapy directed near or toward the pelvis. The impact on the ovarian reserve is related to the accelerated depletion of the primordial germ cell pool resulting from these therapies. Nonsurgical approaches to fertility preservation, including embryo cryopreservation from in vitro fertilization, oocyte cryopreservation from controlled ovarian hyperstimulation, and in vitro maturation of oocytes, are discussed. Surgical approaches such as conservative gynecologic surgery, ovarian transposition, and ovarian tissue cryopreservation are reviewed. Guidelines from the American Society for Reproductive Medicine and the American Society of Clinical Oncology classify these treatments into established and experimental procedures, and they provide the practitioner with an optimal approach to preserve the fertility of these patients before the initiation of their cancer therapies.

KEYWORDS

Fertility preservation - embryo cryopreservation - oocyte cryopreservation - ovarian tissue cryopreservation - gonadotoxicity

REFERENCES

• 1 Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M J. Cancer statistics, 2009.  CA Cancer J Clin. 2009;  59 (4) 225-249
• 2 Bleyer W A. The impact of childhood cancer on the United States and the world.  CA Cancer J Clin. 1990;  40 (6) 355-367
• 3 Speroff L, Fritz M. Clinical Gynecologic Endocrinology and Infertility. 7th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2005
• 4 Bokemeyer C, Schmoll H J, van Rhee J, Kuczyk M, Schuppert F, Poliwoda H. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.  Ann Hematol. 1994;  68 (3) 105-110
• 5 Lobo R A. Potential options for preservation of fertility in women.  N Engl J Med. 2005;  353 (1) 64-73
• 6 Grigsby P W, Russell A, Bruner D et al. Late injury of cancer therapy on the female reproductive tract.  Int J Radiat Oncol Biol Phys. 1995;  31 (5) 1281-1299
• 7 Crictchley H, Hamish B. Safety of pregnancy during and after cancer treatment.  J Natl Cancer Inst Monogr. 2005;  34 64
• 8 Wallace W H, Thomson A B, Saran F, Kelsey T W. Predicting age of ovarian failure after radiation to a field that includes the ovaries.  Int J Radiat Oncol Biol Phys. 2005;  62 (3) 738-744
• 9 Mattle V, Behringer K, Engert A, Wildt L. Female fertility after cytotoxic therapy—protection of ovarian function during chemotherapy of malignant and non-malignant diseases.  Eur J Haematol Suppl. 2005;  66 (66) 77-82
• 10 Slavin S, Nagler A, Aker M, Shapira M Y, Cividalli G, Or R. Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders.  Rev Clin Exp Hematol. 2001;  5 (2) 135-146
• 11 Ethics Committee of the American Society for Reproductive Medicine . Fertility preservation and reproduction in cancer patients.  Fertil Steril. 2005;  83 (6) 1622-1628
• 12 Lee S J, Schover L R, Partridge A H American Society of Clinical Oncology et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients.  J Clin Oncol. 2006;  24 (18) 2917-2931
• 13 Centers for Disease Control and Prevention .Assisted reproductive technology success rates: national summary and fertility clinic reports. Available at: http://www.sart.org
• 14 Yue W, Santen R J, Wang J P et al. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis.  J Steroid Biochem Mol Biol. 2003;  86 (3–5) 477-486
• 15 Oktay K, Hourvitz A, Sahin G et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy.  J Clin Endocrinol Metab. 2006;  91 (10) 3885-3890
• 16 Porcu E, Venturoli S. Progress with oocyte cryopreservation.  Curr Opin Obstet Gynecol. 2006;  18 (3) 273-279
• 17 Chen S U, Lien Y R, Chao K H, Ho H N, Yang Y S, Lee T Y. Effects of cryopreservation on meiotic spindles of oocytes and its dynamics after thawing: clinical implications in oocyte freezing—a review article.  Mol Cell Endocrinol. 2003;  202 (1–2) 101-107
• 18 Vincent C, Pickering S J, Johnson M H. The hardening effect of dimethylsulphoxide on the mouse zona pellucida requires the presence of an oocyte and is associated with a reduction in the number of cortical granules present.  J Reprod Fertil. 1990;  89 (1) 253-259
• 19 Fabbri R, Porcu E, Marsella T, Rocchetta G, Venturoli S, Flamigni C. Human oocyte cryopreservation: new perspectives regarding oocyte survival.  Hum Reprod. 2001;  16 (3) 411-416
• 20 Kinzer D, Alper M, Barrett B. Donor oocyte cryopreservation and subsequent pre-implentation genetic diagnosis of resulting embryos results in high pregnancy rates with a minimum number of embryos transferred.  Fertil Steril. 2008;  90 (Suppl 1) 524
• 21 Grifo J A, Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients.  Fertil Steril. 2010;  93 (2) 391-396
• 22 Huang J Y, Tulandi T, Holzer H, Tan S L, Chian R C. Combining ovarian tissue cryobanking with retrieval of immature oocytes followed by in vitro maturation and vitrification: an additional strategy of fertility preservation.  Fertil Steril. 2008;  89 (3) 567-572
• 23 Surveillance, Epidemiology and End Results. Available at: http://seer.cancer.gov
• 24 Magrina J F, Goodrich M A, Weaver A L, Podratz K C. Modified radical hysterectomy: morbidity and mortality.  Gynecol Oncol. 1995;  59 (2) 277-282
• 25 Gien L T, Covens A. Fertility-sparing options for early stage cervical cancer.  Gynecol Oncol. 2010;  117 (2) 350-357
• 26 Dargent D, Martin X, Sacchetoni A, Mathevet P. Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients.  Cancer. 2000;  88 (8) 1877-1882
• 27 Shepherd J H, Mould T, Oram D H. Radical trachelectomy in early stage carcinoma of the cervix: outcome as judged by recurrence and fertility rates.  BJOG. 2001;  108 (8) 882-885
• 28 Shepherd J H, Spencer C, Herod J, Ind T E. Radical vaginal trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancer—cumulative pregnancy rate in a series of 123 women.  BJOG. 2006;  113 (6) 719-724
• 29 Plante M, Renaud M C, François H, Roy M. Vaginal radical trachelectomy: an oncologically safe fertility-preserving surgery. An updated series of 72 cases and review of the literature.  Gynecol Oncol. 2004;  94 (3) 614-623
• 30 Hertel H, Köhler C, Grund D German Association of Gynecologic Oncologists (AGO) et al. Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: prospective multicenter study of 100 patients with early cervical cancer.  Gynecol Oncol. 2006;  103 (2) 506-511
• 31 Plante M. Vaginal radical trachelectomy: an update.  Gynecol Oncol. 2008;  111 (2 Suppl) S105-S110
• 32 Marchiole P, Benchaib M, Buenerd A, Lazlo E, Dargent D, Mathevet P. Oncological safety of laparoscopic-assisted vaginal radical trachelectomy (LARVT or Dargent's operation): a comparative study with laparoscopic-assisted vaginal radical hysterectomy (LARVH).  Gynecol Oncol. 2007;  106 (1) 132-141
• 33 Covens A, Rosen B, Murphy J et al. How important is removal of the parametrium at surgery for carcinoma of the cervix?.  Gynecol Oncol. 2002;  84 (1) 145-149
• 34 Stegeman M, Louwen M, van der Velden J et al. The incidence of parametrial tumor involvement in select patients with early cervix cancer is too low to justify parametrectomy.  Gynecol Oncol. 2007;  105 (2) 475-480
• 35 Rob L, Charvat M, Robova H et al. Less radical fertility-sparing surgery than radical trachelectomy in early cervical cancer.  Int J Gynecol Cancer. 2007;  17 (1) 304-310
• 36 Bisseling K C, Bekkers R L, Rome R M, Quinn M A. Treatment of microinvasive adenocarcinoma of the uterine cervix: a retrospective study and review of the literature.  Gynecol Oncol. 2007;  107 (3) 424-430
• 37 Milliken D A, Shepherd J H. Fertility preserving surgery for carcinoma of the cervix.  Curr Opin Oncol. 2008;  20 (5) 575-580
• 38 Boss E A, van Golde R J, Beerendonk C C, Massuger L F. Pregnancy after radical trachelectomy: a real option?.  Gynecol Oncol. 2005;  99 (3 Suppl 1) S152-S156
• 39 Chiva L, Lapuente F, González-Cortijo L et al. Sparing fertility in young patients with endometrial cancer.  Gynecol Oncol. 2008;  111 (2 Suppl) S101-S104
• 40 Kim Y B, Holschneider C H, Ghosh K, Nieberg R K, Montz F J. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature.  Cancer. 1997;  79 (2) 320-327
• 41 Ushijima K, Yahata H, Yoshikawa H et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.  J Clin Oncol. 2007;  25 (19) 2798-2803
• 42 Kauff N D. How should women with early-onset endometrial cancer be evaluated for Lynch syndrome?.  J Clin Oncol. 2007;  25 (33) 5143-5146
• 43 Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I. Coexisting ovarian malignancy in young women with endometrial cancer.  Obstet Gynecol. 2005;  106 (4) 693-699
• 44 Simon B, Lee S J, Partridge A H, Runowicz C D. Preserving fertility after cancer.  CA Cancer J Clin. 2005;  55 (4) 211-228 quiz 263-264
• 45 Schilder J M, Thompson A M, DePriest P D et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy.  Gynecol Oncol. 2002;  87 (1) 1-7
• 46 Marhhom E, Cohen I. Fertility preservation options for women with malignancies.  Obstet Gynecol Surv. 2007;  62 (1) 58-72
• 47 Scott S M, Schlaff W. Laparoscopic medial oophoropexy prior to radiation therapy in an adolescent with Hodgkin's disease.  J Pediatr Adolesc Gynecol. 2005;  18 (5) 355-357
• 48 Morice P, Juncker L, Rey A, El-Hassan J, Haie-Meder C, Castaigne D. Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination.  Fertil Steril. 2000;  74 (4) 743-748
• 49 Kuohung W, Ram K, Cheng D M, Marcus K J, Diller L R, Laufer M R. Laparoscopic oophoropexy prior to radiation for pediatric brain tumor and subsequent ovarian function.  Hum Reprod. 2008;  23 (1) 117-121
• 50 Williams R S, Littell R D, Mendenhall N P. Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease.  Cancer. 1999;  86 (10) 2138-2142
• 51 Guglielmi R, Calzavara F, Pizzi G B et al. Ovarian function after pelvic lymph node irradiation in patients with Hodgkin's disease submitted to oophoropexy during laparotomy.  Eur J Gynaecol Oncol. 1980;  1 (2) 99-107
• 52 Khan M A, Dahill S W, Stewart K S. Primary Hodgkin's disease of the ovary. Case report.  Br J Obstet Gynaecol. 1986;  93 (12) 1300-1301
• 53 Osborne B M, Robboy S J. Lymphomas or leukemia presenting as ovarian tumors. An analysis of 42 cases.  Cancer. 1983;  52 (10) 1933-1943
• 54 Meirow D, Hardan I, Dor J et al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients.  Hum Reprod. 2008;  23 (5) 1007-1013
• 55 Oktay K, Oktem O. Ovarian cryopreservation and transplantation for fertility preservation for medical indications: report of an ongoing experience.  Fertil Steril. 2010;  93 (3) 762-768
• 56 Donnez J, Martinez-Madrid B, Jadoul P, Van Langendonckt A, Demylle D, Dolmans M M. Ovarian tissue cryopreservation and transplantation: a review.  Hum Reprod Update. 2006;  12 (5) 519-535
• 57 Donnez J, Dolmans M M, Demylle D et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue.  Lancet. 2004;  364 (9443) 1405-1410
• 58 Meirow D, Levron J, Eldar-Geva T et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy.  N Engl J Med. 2005;  353 (3) 318-321
• 59 Andersen C Y, Rosendahl M, Byskov A G et al. Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue.  Hum Reprod. 2008;  23 (10) 2266-2272
• 60 Demeestere I, Simon P, Emiliani S, Delbaere A, Englert Y. Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin's disease.  Oncologist. 2007;  12 (12) 1437-1442
• 61 Oktay K, Buyuk E, Veeck L et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue.  Lancet. 2004;  363 (9412) 837-840
• 62 Sonmezer M, Oktay K. Fertility preservation in female patients.  Hum Reprod Update. 2004;  10 (3) 251-266
• 63 Oktay K, Sonmezer M. Ovarian tissue banking for cancer patients: fertility preservation, not just ovarian cryopreservation.  Hum Reprod. 2004;  19 (3) 477-480
• 64 Oktay K, Economos K, Kan M, Rucinski J, Veeck L, Rosenwaks Z. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm.  JAMA. 2001;  286 (12) 1490-1493
• 65 Jadoul P, Donnez J, Dolmans M M, Squifflet J, Lengele B, Martinez-Madrid B. Laparoscopic ovariectomy for whole human ovary cryopreservation: technical aspects.  Fertil Steril. 2007;  87 (4) 971-975